MetaCap

Cullinan Therapeutics (CGEM) vs Valneva (VALN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cullinan Therapeutics (CGEM) has outperformed Valneva (VALN) over the past year, losing 6.1% versus a loss of 40.1%. Over five years, CGEM leads with a -51.2% price change compared with -91.3% for VALN. Cullinan Therapeutics is the larger company by market cap ($577.1 million vs $490.9 million), about 1.2 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CGEM-6.12%VALN-40.14%
+152%+49%-54%
Nov 21, 20251 yearNov 20, 2026
CGEM-54.34%VALN-89.45%
+52%-23%-99%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CGEM versus VALN key metrics
MetricCGEMVALN
Share price$8.89$5.16
Market cap$577.15M$490.86M
1-day change-1.98%-3.82%
YTD return-14.11%-41.50%
1-year return-6.12%-40.14%
5-year return-51.21%-91.34%
Forward P/E—4.34
EPS (TTM)$-3.09$-2.10
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-219.88M—
52-week high$23.19$12.18
52-week low$8.47$4.75
Distance from 52-week high-61.66%-57.64%
Analyst consensusstrong_buynone
Avg. price target upside+285.49%+137.98%
Average volume997.14K23.10K
Shares outstanding64.92M95.13M
Employees109620
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CGEM has outperformed VALN by 34.0 percentage points over the past year.

About Cullinan Therapeutics

CGEM stock →

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees

About Valneva

VALN stock →

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees

CGEM vs VALN FAQ

Which is bigger, Cullinan Therapeutics or Valneva?

Cullinan Therapeutics (CGEM) is larger, with a market capitalization of $577.15M compared with $490.86M for Valneva (VALN).

Which stock has performed better over the past year, CGEM or VALN?

CGEM returned -6.12% over the past 12 months, compared with -40.14% for VALN (price return, excluding dividends). Past performance does not predict future results.

Are Cullinan Therapeutics and Valneva in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons